Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. What Happens If You Use Expired Semaglutide? Wondering what ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking semaglutide. Reading time 3 minutes What if you could take Ozempic or ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the ...

Initially 2–3mg once daily; may adjust at intervals of at least 24hrs by 1mg/day. Usual range: 1–6mg/day; max 6mg/day. Elderly, debilitated, hypotensive, severe renal or hepatic impairment: 0.5mg ...

A new drug currently known as NG101 reduced nausea and vomiting in patients with obesity using GLP-1s by 40% and 67%, respectively, based on data from a phase 2 trial presented at the Obesity ...

WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Neurogastrx, Inc., today presented proof-of-concept data from its placebo-controlled Phase 2 clinical study of NG101 (metopimazine mesylate), an oral, ...